Clinical Trials

Phase 2 Active not recruiting

285 enrolled

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

423 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT05593497 2025-04-16

SNARE

Phase 2 Recruiting

30 enrolled

Prostatic Neoplasms

NCT03903835 2025-04-09

ProBio

Phase 3 Recruiting

750 enrolled

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Phase 2 Recruiting

120 enrolled

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

NCT02423603 2025-03-10

PAKT

71 enrolled

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05348577 2025-01-27

CAPItello280

1,035 enrolled

Phase 2 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT05008055 2024-12-20

CAPITAL

30 enrolled 15 charts

Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02338622 2024-09-26

ComPAKT

60 enrolled

Advanced Cancer

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2 Recruiting

42 enrolled

Breast Neoplasms

NCT04958226 2024-01-25

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

21 enrolled

Other solid neoplasm

Solid Tumour

NCT02117167 2024-01-10

SAFIR02_Lung

999 enrolled

Thoracic

Non-small Cell Lung Cancer Metastatic

NCT03310541 2023-05-06

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

12 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT02576444 2022-12-28

OLAPCO

Phase 2 Terminated

67 enrolled 10 charts

Tumor-Agnostic

Neoplasms

NCT04742036 2022-08-19

Capivasertib China PK Study

16 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

27 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT04944771 2022-05-09

Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants

Other hematologic neoplasm

48 enrolled

Hematologic Neoplasms

NCT02121639 2022-05-05

ProCAID

Phase 1/2 Completed

160 enrolled

Prostatic Neoplasms

NCT04712396 2021-04-09

A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body

11 enrolled

BreastGenitourinary

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

NCT02451956 2019-12-30

Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

21 enrolled

Gastrointestinal

Advanced Gastric Cancer

NCT03182634 2019-01-22

plasmaMATCH

Phase 2 Unknown

1,150 enrolled

Advanced Breast Cancer

NCT02077569 2017-05-04

STAKT

48 enrolled

Breast Neoplasms

NCT01895946 2016-05-25

OAK

33 enrolled 14 charts

Advanced Solid Malignancy,

NCT01353781 2016-04-26

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies